Proposed Agenda & Faculty, April 28-29 2023
07:00am
Registration
08:30am
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I
08:40am
MPN classification by WHO vs. ICC, what is the impact?
Andrew T. Kuykendall, Moffitt Cancer Center, Tampa, FL
09:00am
Indolent and Advanced Systemic Mastocytosis: Old and New Therapies
William Shomali, Stanford University Medical Center, CA
09:20am
Myeloid/Lymphoid Neoplasms With Eosinophilia
Pankit Vachhani, O’Neal Comprehensive Cancer Center, AL
09:40am
Novel Prognostication and Therapies For ET
Laura Michaelis, Froedtert Hospital, Milwaukee, WI
10:00am
Panel Discussion
10:20am
Coffee Break
10:50am
Independent discussion supported by CTI
11:40am
Room refresh and Poster/exhibits
Session II
12:10pm
Choices and Goals of Therapies for PV
Lucia Masarova, MD Anderson Cancer Center, Houston, TX
12:30pm
How I Prognosticate in MF
Abdulraheem Yacoub, The University of Kansas Health System, Kansas City, KS
12:50pm
Ruxolitinib and Fedratinib in 2023
Raajit Rampal,Memorial Sloan Kettering Cancer Center, NY
13:10pm
Pacritinib and Momelotinib in 2023
John Mascarenhas, Mount Sinai, NY
13:30pm
Panel Discussion
13:50pm
Lunch Break
14:50pm
Independent discussion supported by GSK
15:40pm
Room refresh and Poster/exhibits
Session III
16:10pm
Novel Combination Therapies in Development for MF
Naveen Pemmaraju, MD Anderson Cancer Center, Houston, TX
16:30pm
What to do When Blasts Increase in MPN
Prithviraj Bose, MD Anderson Cancer Center, Houston, TX
16:50pm
Anemia of myelofibrosis: current and emerging therapies
Stephen Oh, Washington University School of Medicine, Saint Louis
17:10pm
Will novel therapies in development after JAK inhibitors change the outlook for MF?
Jeanne Palmer, Mayo Clinic, Scottdale, AR
17:30pm
Panel Discussion
17:50pm
Room refresh and Poster/exhibits
08:00am
Registration
Session I
Debate: Clash of the titans
09:00am
MDS classification: WHO
Joseph Khoury, University of Nebraska Medical Center, Omaha, NE
09:10am
MDS classification: ICC 2022
Sanam Loghavi, MD Anderson Cancer Center, Houston, TX
09:20am
Panel Discussion
Debate: Risk stratification in MDS
09:30am
IPSS-M is ready for prime time use?
J Luis Aguirre, , Moffit Cancer Center, FL
09:40am
IPSS-M not ready for prime time use?
Somedeb Ball, Moffit Cancer Center, FL
09:50am
Apples and oranges? Unifying and making sense of response assessment in MDS
Amer Zeidan, Yale School of Medicine, CT
10:10am
Panel Discussion
10:20am
Coffee Break
10:50am
Independent discussion supported by Geron
11:40am
Room refresh and Poster/exhibits
Session II
12:10pm
Ahead of the game: Building clinics and Clinical trials in CCUS and CHIP
Uma Borate, The James Cancer Hospital, OH
12:30pm
The new kid on the block: Role of TGF-B inhibitors in MDS
Rami Komrokji, Moffit Cancer Center, FL
12:50pm
Coming soon? Telomerase inhibitors for lower risk MDS
Yazan Madanat, University of Texas Sothern Medical Centre, TX
13:10pm
Are we ready to make the change? Oral hypomethylating agents
Sangeetha Venugopal, University of Miami,FL
13:30pm
Panel Discussion
13:50pm
Lunch Break
14:50pm
Independent discussion supported by BMS
15:40pm
Room refresh and Poster/exhibits
Session III
16:10pm
Don’t eat me? update on Magrolimab clinical trials for MDS
David Sallman, Moffit Cancer Center, FL
16:30pm
A dual punch? Update on sabatolimab development in MDS
Andrew Brunner, Massachusetts General Hospital, MA
16:50pm
Is it ready for prime time? Venetoclax for treatment of MDS
Guillermo Montalban Bravo, MD Anderson Cancer Center, TX
17:10pm
Panel Discussion
17:30pm
Coffee Break
Session IV
17:50pm
What to do Before and after Allogeneic stem cell transplant for MDS
Bart Scott, Fred Hutchinson Cancer Center, WA
18:10pm
Can we stand alone: MDS/MPN
Aref Al-Kali, Mayo Clinic, MN
18:30pm
The tip of the iceberg: MRD assessment in MDS
Zhuoer Xie, Moffitt Cancer Center, FL
